Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Lixte Biotechnology Holdings, Inc. (LIXT) had Income from Continuous Operations of $-1.98M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-2.03M |
|
-- |
|
-- |
|
$1.80M |
|
$-1.80M |
|
$-0.18M |
|
$-1.98M |
|
$-1.98M |
|
$-1.98M |
|
|
Income from Continuous Operations |
$-1.98M |
$-1.98M |
|
$-1.98M |
|
$-1.80M |
|
$-1.80M |
|
6.17M |
|
6.17M |
|
$-0.33 |
|
$-0.33 |
|
| Balance Sheet Financials | |
$5.43M |
|
-- |
|
-- |
|
$5.43M |
|
$0.52M |
|
-- |
|
-- |
|
$0.52M |
|
$2.36M |
|
$4.91M |
|
$4.91M |
|
5.70M |
|
| Cash Flow Statement Financials | |
$-1.98M |
|
$-2.64M |
|
$6.47M |
|
$1.04M |
|
$2.89M |
|
$1.85M |
|
$0.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.98M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-83.95% |
|
-40.31% |
|
-36.44% |
|
-40.31% |
|
$0.86 |
|
$-0.32 |
|
$-0.32 |
|